H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $41 from $45 and keeps a Buy rating on the shares following the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics reports Q3 EPS ($1.13) , consensus (79c)
- Cartesian announces Phase 2b trial of Descartes-08 achieved primary endpoint
- Cartesian Therapeutics announces employment inducement grant
- Three new option listings and eighteen option delistings on September 23rd
- Cartesian receives FDA Rare Pediatric Disease Designation for Descartes-08
Questions or Comments about the article? Write to editor@tipranks.com